In recent days, Boston Scientific announced a forthcoming CFO change, a Cambridge biotech undertook a 1-for-20 reverse stock ...

Boston Scientific said that while tariffs pose “unfortunate” headwinds—which are poised to add about $200 million to the cost ...

A developer that specializes in office to lab conversions secured the largest life science lease of 2025 in Boston with a ...

Roche’s drug production operations are set to benefit from the company’s updated U.S. strategy, including with “expanded and ...

Some tariffs remain in place against key U.S. trading partners, but others have been postponed to give nations time to ...

Seattle, WA - NephroDI Therapeutics (NephroDI), a pharmaceutical company focusing on kidney disorders, announces that its ...

President Trump’s financial fight with Harvard University risks economic fallout far beyond the ornate gates surrounding ...

Two new biotech CEOs. We only saw two changes ... Ascidian Therapeutics, a Boston-based gene therapy company utilising RNA exon editing, announced multiple appointments this month, including ...

Boston Scientific raised its annual profit forecast and said strong demand for its medical devices would buffer a potential $200 million tariff-related hit, sending its shares up nearly 6% on ...

Boston Scientific also announced that it has appointed Jon Monson, currently senior vice president of investor relations, to the role of chief financial officer, effective June 30. He succeeds Dan ...

In 2014, Chinese companies had fewer than 500 drugs ... s the end of Kendall Square as we know it. What if biotech never bounces back? - The Boston Globe ...